Social impacts of transport: literature review and the state of the practice of transport appraisal in the Netherlands and the United Kingdom KT Geurs, W Boon, B Van Wee Transport reviews 29 (1), 69-90, 2009 | 230 | 2009 |
Towards a typology of intermediaries in sustainability transitions: A systematic review and a research agenda P Kivimaa, W Boon, S Hyysalo, L Klerkx Research Policy 48 (4), 1062-1075, 2019 | 137 | 2019 |
Demand articulation in emerging technologies: intermediary user organisations as co-producers? WPC Boon, EHM Moors, S Kuhlmann, REHM Smits Research Policy 40 (2), 242-252, 2011 | 118 | 2011 |
Demand, challenges, and innovation. Making sense of new trends in innovation policy W Boon, J Edler Science and Public Policy 45 (4), 435-447, 2018 | 85 | 2018 |
Demand articulation in intermediary organisations: The case of orphan drugs in the Netherlands WPC Boon, EHM Moors, S Kuhlmann, REHM Smits Technological forecasting and social change 75 (5), 644-671, 2008 | 79 | 2008 |
The role of users in innovation in the pharmaceutical industry REHM Smits, WPC Boon Drug discovery today 13 (7-8), 353-359, 2008 | 76 | 2008 |
Exploring emerging technologies using metaphors–a study of orphan drugs and pharmacogenomics W Boon, E Moors Social science & medicine 66 (9), 1915-1927, 2008 | 71 | 2008 |
Carsharing business models in Germany: characteristics, success and future prospects K Münzel, W Boon, K Frenken, T Vaskelainen Information Systems and e-Business Management 16 (2), 271-291, 2018 | 62 | 2018 |
Stakeholder interaction within research consortia on emerging technologies: Learning how and what? A Roelofsen, WPC Boon, RR Kloet, JEW Broerse Research Policy 40 (3), 341-354, 2011 | 56 | 2011 |
User-led innovation in civic energy communities GW de Vries, WPC Boon, A Peine Environmental Innovation and Societal Transitions 19, 51-65, 2016 | 53 | 2016 |
Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe WPC Boon, EHM Moors, A Meijer, H Schellekens Clinical Pharmacology & Therapeutics 88 (6), 848-853, 2010 | 53 | 2010 |
Exploring dynamics and strategies of niche protection WPC Boon, EHM Moors, AJ Meijer Research Policy 43 (4), 792-803, 2014 | 48 | 2014 |
Use of the conditional marketing authorization pathway for oncology medicines in Europe J Hoekman, WPC Boon, JC Bouvy, HC Ebbers, JP de Jong, ML De Bruin Clinical Pharmacology & Therapeutics 98 (5), 534-541, 2015 | 44 | 2015 |
Balancing divergence and convergence in transdisciplinary research teams WPC Boon, MMH Chappin, J Perenboom Environmental science & policy 40, 57-68, 2014 | 42 | 2014 |
Passing the baton: How intermediaries advance sustainability transitions in different phases P Kivimaa, S Hyysalo, W Boon, L Klerkx, M Martiskainen, J Schot Environmental Innovation and Societal Transitions 31, 110-125, 2019 | 41 | 2019 |
Influence of 3D printing on transport: a theory and experts judgment based conceptual model W Boon, B Van Wee Transport Reviews 38 (5), 556-575, 2018 | 37 | 2018 |
The role of patient advocacy organisations in neuromuscular disease R&D–The case of the Dutch neuromuscular disease association VSN W Boon, R Broekgaarden Neuromuscular disorders 20 (2), 148-151, 2010 | 34 | 2010 |
User-producer interactions in emerging pharmaceutical and food innovations EHM Moors, WPC Boon, R Nahuis, RLJ Vandeberg International journal of innovation management 12 (03), 459-487, 2008 | 30 | 2008 |
Institutional entrepreneurship in the platform economy: How Uber tried (and failed) to change the Dutch taxi law P Pelzer, K Frenken, W Boon Environmental Innovation and Societal Transitions 33, 1-12, 2019 | 26 | 2019 |
Learning to shield–Policy learning in socio-technical transitions WPC Boon, S Bakker Environmental Innovation and Societal Transitions 18, 181-200, 2016 | 26 | 2016 |